ALLAKOS INC. news, videos and press releases
For more news please use our advanced search feature.
ALLAKOS INC. - More news...
ALLAKOS INC. - More news...
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
- Allakos Announces a Restructuring to Focus on Development of AK006
- Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
- Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
- Allakos Appoints Neil Graham to its Board of Directors
- Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
- Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
- Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
- Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
- Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
- Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
- Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
- Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
- Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)
- Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
- Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
- Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
- Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
- Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases
- Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
- Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results
- Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation
- Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting
- Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results
- Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)